[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
    "summary": "Health care stocks edged higher late Friday afternoon with the NYSE Health Care Index edging up 0.1%",
    "url": "https://finnhub.io/api/news?id=c24a77f6ba8cb536c44e106345739445f3418c80ed5cd13e38936b0adfdd8259",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757100681,
      "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
      "id": 136651488,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks edged higher late Friday afternoon with the NYSE Health Care Index edging up 0.1%",
      "url": "https://finnhub.io/api/news?id=c24a77f6ba8cb536c44e106345739445f3418c80ed5cd13e38936b0adfdd8259"
    }
  },
  {
    "ts": null,
    "headline": "WHO adds weight loss drugs to essential medicines list",
    "summary": "The Inclusion of the weight loss medicine to the list should boost access to the drugs in poorer countries",
    "url": "https://finnhub.io/api/news?id=d430f684ecc249925765696a143e5f70e96989cb3d52750d10740bfec5d1d294",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757100217,
      "headline": "WHO adds weight loss drugs to essential medicines list",
      "id": 136652821,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Inclusion of the weight loss medicine to the list should boost access to the drugs in poorer countries",
      "url": "https://finnhub.io/api/news?id=d430f684ecc249925765696a143e5f70e96989cb3d52750d10740bfec5d1d294"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of September 7",
    "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full article here.",
    "url": "https://finnhub.io/api/news?id=ff914b676260c3d875ed7f5add1e0b873c78fd74eee4f340db91c840588fe9c1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757099009,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of September 7",
      "id": 136651455,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full article here.",
      "url": "https://finnhub.io/api/news?id=ff914b676260c3d875ed7f5add1e0b873c78fd74eee4f340db91c840588fe9c1"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Friday Afternoon",
    "summary": "Health care stocks advanced Friday afternoon, with the NYSE Health Care Index up 0.2% and the Health",
    "url": "https://finnhub.io/api/news?id=50bc9ae80eec308ebecbde5132dfd1c5742664389aa26b29b2dab24fc3cb4c3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757097969,
      "headline": "Sector Update: Health Care Stocks Rise Friday Afternoon",
      "id": 136652822,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks advanced Friday afternoon, with the NYSE Health Care Index up 0.2% and the Health",
      "url": "https://finnhub.io/api/news?id=50bc9ae80eec308ebecbde5132dfd1c5742664389aa26b29b2dab24fc3cb4c3f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Keep It Low So I Can Keep Accumulating (Rating Upgrade)",
    "summary": "Novo Nordisk's Q2 growth, strong market share, and innovative drug pipeline make it a top stock pick. Click here to find out why NVO stock is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=fbcdf33a9a2151b5b3a075eb9e680ba551a83a767ca5061b229075b4437e886c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757095833,
      "headline": "Novo Nordisk: Keep It Low So I Can Keep Accumulating (Rating Upgrade)",
      "id": 136651233,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305431/image_2158305431.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk's Q2 growth, strong market share, and innovative drug pipeline make it a top stock pick. Click here to find out why NVO stock is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=fbcdf33a9a2151b5b3a075eb9e680ba551a83a767ca5061b229075b4437e886c"
    }
  },
  {
    "ts": null,
    "headline": "Jefferies Sees Huge Potential in Eli Lilly’s (LLY) New Weight-Loss Pill",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the top 10 mega-cap stocks to buy according to hedge funds.. Eli Lilly and Company (NYSE:LLY) is stirring up major excitement on Wall Street with its upcoming weight-loss pill, Orforglipron. Jefferies analyst Akash Tewari believes the drug could generate over $10 billion in yearly sales once it […]",
    "url": "https://finnhub.io/api/news?id=e5a246945435fb127fc9c1140a708b10a45bae45e9639cadba65624ffc0da555",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757088334,
      "headline": "Jefferies Sees Huge Potential in Eli Lilly’s (LLY) New Weight-Loss Pill",
      "id": 136652823,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the top 10 mega-cap stocks to buy according to hedge funds.. Eli Lilly and Company (NYSE:LLY) is stirring up major excitement on Wall Street with its upcoming weight-loss pill, Orforglipron. Jefferies analyst Akash Tewari believes the drug could generate over $10 billion in yearly sales once it […]",
      "url": "https://finnhub.io/api/news?id=e5a246945435fb127fc9c1140a708b10a45bae45e9639cadba65624ffc0da555"
    }
  },
  {
    "ts": null,
    "headline": "World Health Organization Adds Ozempic, Mounjaro to Essential Medicines List",
    "summary": "The World Health Organization said Friday it has added Novo Nordisk's (NVO) Ozempic and Eli Lilly's",
    "url": "https://finnhub.io/api/news?id=6a0d3cc6bec7cc199d4791ee9d5fe4cc407315a65fea6c3e809433b3caaf6403",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757084935,
      "headline": "World Health Organization Adds Ozempic, Mounjaro to Essential Medicines List",
      "id": 136648869,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The World Health Organization said Friday it has added Novo Nordisk's (NVO) Ozempic and Eli Lilly's",
      "url": "https://finnhub.io/api/news?id=6a0d3cc6bec7cc199d4791ee9d5fe4cc407315a65fea6c3e809433b3caaf6403"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly Stock a Buy After Gaining 5% in 1 Day?",
    "summary": "The company's innovative engine continues to function well.",
    "url": "https://finnhub.io/api/news?id=e18dad0b371f0d8188ef884f0e6b269c2bacdbca6d1b437713f3529f298ee063",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757080800,
      "headline": "Is Eli Lilly Stock a Buy After Gaining 5% in 1 Day?",
      "id": 136648870,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company's innovative engine continues to function well.",
      "url": "https://finnhub.io/api/news?id=e18dad0b371f0d8188ef884f0e6b269c2bacdbca6d1b437713f3529f298ee063"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Vs Eli Lilly: Novo A Clear Winner",
    "summary": "Many investors favour Eli Lilly (LLY), but I will argue in this report that Novo stock outperforms Lilly in almost every aspect, while trading at a significantly lower price. Read on here.",
    "url": "https://finnhub.io/api/news?id=0f86208a3ae3c68e583cf8a5993781c72142c718d70177e0ef5bd1f949ea7d50",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757077804,
      "headline": "Novo Nordisk Vs Eli Lilly: Novo A Clear Winner",
      "id": 136649698,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1940134895/image_1940134895.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Many investors favour Eli Lilly (LLY), but I will argue in this report that Novo stock outperforms Lilly in almost every aspect, while trading at a significantly lower price. Read on here.",
      "url": "https://finnhub.io/api/news?id=0f86208a3ae3c68e583cf8a5993781c72142c718d70177e0ef5bd1f949ea7d50"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly And Company (LLY) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)",
    "summary": "Get insights from Eli Lilly's 2025 strategy at the Wells Fargo Healthcare Conference:",
    "url": "https://finnhub.io/api/news?id=341487434225078447753b5516c8146f49f19970748cbcb65a33b380687d958f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757074300,
      "headline": "Eli Lilly And Company (LLY) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)",
      "id": 136649473,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Get insights from Eli Lilly's 2025 strategy at the Wells Fargo Healthcare Conference:",
      "url": "https://finnhub.io/api/news?id=341487434225078447753b5516c8146f49f19970748cbcb65a33b380687d958f"
    }
  },
  {
    "ts": null,
    "headline": "EMA warns of rise in illegal weight loss drugs marketed online",
    "summary": "The alert is part of a growing trend in the prevalence of counterfeit and unregulated GLP-1RAs.",
    "url": "https://finnhub.io/api/news?id=1bca7ac2158dc90c4c8aee6bbaa259a951a4bdbdff0ae4040ca243ddc4f2af35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757072630,
      "headline": "EMA warns of rise in illegal weight loss drugs marketed online",
      "id": 136647684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The alert is part of a growing trend in the prevalence of counterfeit and unregulated GLP-1RAs.",
      "url": "https://finnhub.io/api/news?id=1bca7ac2158dc90c4c8aee6bbaa259a951a4bdbdff0ae4040ca243ddc4f2af35"
    }
  },
  {
    "ts": null,
    "headline": "Why weight-loss 'wonder drugs' aren't 'wonder stocks' — yet",
    "summary": "If health plans are pressured to expand their coverage, GLP-1 makers can escape their Wall Street funk.",
    "url": "https://finnhub.io/api/news?id=09aaf6b8bb9161b1152acccd1708ed781802cbc8906f9ae07ab421aa8ae13d83",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757070006,
      "headline": "Why weight-loss 'wonder drugs' aren't 'wonder stocks' — yet",
      "id": 136647786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "If health plans are pressured to expand their coverage, GLP-1 makers can escape their Wall Street funk.",
      "url": "https://finnhub.io/api/news?id=09aaf6b8bb9161b1152acccd1708ed781802cbc8906f9ae07ab421aa8ae13d83"
    }
  },
  {
    "ts": null,
    "headline": "2 S&P 500 Dividend Stocks That Could Climb More Than 20% According to Wall Street Analysts",
    "summary": "Consensus price targets set by experts who follow these businesses are way above their recent prices.",
    "url": "https://finnhub.io/api/news?id=ae7afe6ec57300aa03a9a0e4d7b8a6091bd433b8717bf3fa7e5b6e4731348c7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757064540,
      "headline": "2 S&P 500 Dividend Stocks That Could Climb More Than 20% According to Wall Street Analysts",
      "id": 136647787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Consensus price targets set by experts who follow these businesses are way above their recent prices.",
      "url": "https://finnhub.io/api/news?id=ae7afe6ec57300aa03a9a0e4d7b8a6091bd433b8717bf3fa7e5b6e4731348c7f"
    }
  },
  {
    "ts": null,
    "headline": "Down 34%, Should You Buy the Dip on Viking Therapeutics?",
    "summary": "Viking aims to enter the billion-dollar weight loss drug market.",
    "url": "https://finnhub.io/api/news?id=1b46c276c9a6bdd7526e0c028923cb36b72866a7c37c090cadcd299ea5b93d80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757063400,
      "headline": "Down 34%, Should You Buy the Dip on Viking Therapeutics?",
      "id": 136647788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking aims to enter the billion-dollar weight loss drug market.",
      "url": "https://finnhub.io/api/news?id=1b46c276c9a6bdd7526e0c028923cb36b72866a7c37c090cadcd299ea5b93d80"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Still A Bargain Despite Kennedy's Anti-Vaccine Attacks",
    "summary": "Pfizer Inc.'s strong Q2 2025 sales defy expectations. Discover analyst insights, growth drivers, and why it's rated Strong Buy. Click for my PFE stock update.",
    "url": "https://finnhub.io/api/news?id=d73fe54fc34318ccf1d3729ec1a04d051d9f77957ff3802476624a400c8c850d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757063226,
      "headline": "Pfizer: Still A Bargain Despite Kennedy's Anti-Vaccine Attacks",
      "id": 136647643,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304540314/image_1304540314.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc.'s strong Q2 2025 sales defy expectations. Discover analyst insights, growth drivers, and why it's rated Strong Buy. Click for my PFE stock update.",
      "url": "https://finnhub.io/api/news?id=d73fe54fc34318ccf1d3729ec1a04d051d9f77957ff3802476624a400c8c850d"
    }
  }
]